SIRT2 and non-small cell lung carcinoma: One study suggests that AK-7, another SIRT2 inhibitor, enhances p53 activity by preventing its deacetylation in non-small cell lung cancer (NSCLC) cells, positioning it as a potential candidate for cancer treatment, particularly for targeting p53-proficient cancers [266].